Depner, Martin
,
Taft, Diana Hazard
Kirjavainen, Pirkka V. http://orcid.org/0000-0001-6119-8768
Kalanetra, Karen M.
Karvonen, Anne M. http://orcid.org/0000-0003-2257-2934
Peschel, Stefanie
Schmausser-Hechfellner, Elisabeth
Roduit, Caroline http://orcid.org/0000-0002-5988-0570
Frei, Remo
Lauener, Roger http://orcid.org/0000-0002-8412-606X
Divaret-Chauveau, Amandine http://orcid.org/0000-0002-2492-9864
Dalphin, Jean-Charles
Riedler, Josef
Roponen, Marjut http://orcid.org/0000-0002-4442-9090
Kabesch, Michael
Renz, Harald http://orcid.org/0000-0003-0602-7215
Pekkanen, Juha
Farquharson, Freda M.
Louis, Petra http://orcid.org/0000-0003-2115-2399
Mills, David A.
von Mutius, Erika
Ege, Markus J. http://orcid.org/0000-0001-6643-3923
Article History
Received: 28 September 2019
Accepted: 8 September 2020
First Online: 2 November 2020
Competing interests
: D.A.M. is a co-founder of Evolve Biosystems, a company focused on diet-based manipulation of the gut microbiota, and BCD Biosciences, a company advancing novel bioactive glycans. Neither Evolve Biosystems nor BCD Biosciences had a role in the conceptualization, design, data collection, analysis or preparation of this paper. M.K. has a patent share on the diagnostic use of SNPs in <i>ORMDL3</i> on chromosome 17q21. H.R. has received research support from DFG, BMBF, EU, Land Hessen, DAAD, ALK, Stiftung Pathobiochemie, Ernst-Wendt-Stiftung, Mead Johnson Nutritional and Beckman Coulter; speaker’s honoraria from Allergopharma, Novartis, Thermo Fisher, Danone, Mead Johnson Nutritional and Bencard; and consulting fees from Bencard and Sterna Biologicals. He is a cofounder of Sterna Biologicals. E.v.M. is listed as an inventor on the following patents: publication number EP 1411977, composition containing bacterial antigens used for the prophylaxis and treatment of allergic diseases, granted on 18 April 2007; publication number EP 1637147, stable dust extract for allergy protection, granted on 10 December 2008; publication number EP 1964570, pharmaceutical compound to protect against allergies and inflammatory diseases, granted on 21 November 2012. E.v.M. is listed as an inventor and has received royalties on the following patent: publication number EP 2361632, specific environmental bacteria for the protection from and/or treatment of allergic, chronic inflammatory and/or autoimmune disorders, granted on 19 March 2014. She has received funding and research support from FrieslandCampina; she has received consultation and speaker fees from OM Pharma, Böhringer Ingelheim International, Peptinnovate, Pharmaventures, Nestlé Deutschland (36 months before publication) and HiPP (future). M.J.E. is a co-inventor on patents for the use of environmental bacteria to prevent asthma (EP000001964570B1, US000009950017B2 and EP000002361632B1). His employer has received investigational products for an intervention study with minimally processed milk from FrieslandCampina.